Advertisement
News
Subscribe to MDT Magazine News

Reportlinker Adds Gene Therapy - Technologies, Markets and Companies

March 7, 2011 11:34 am | by Bio-Medicine.Org | Comments

NEW YORK, March 7, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Gene Therapy - technologies, markets and companies http://www.reportlinker.com/p0203543/Gene-Therapy---technologies-markets-and-companies.html Summary Gene therapy can be...

TOPICS:

Humana CEO sees 2010 compensation slide 6 percent

March 7, 2011 10:45 am | by TOM MURPHY - AP Business Writer - Associated Press | Comments

Health insurer Humana Inc. paid Chairman and CEO Michael B. McCallister 6 percent less last year than in 2009, as a decline in option awards outweighed a bump up in the long-standing executive's performance-related bonus.McCallister, 58, received 2010 compensation valued at $6.1 million from...

NIH study examines best time for healthy HIV-infected people to begin antiretrovirals

March 7, 2011 10:38 am | by EurekAlert | Comments

(NIH/National Institute of Allergy and Infectious Diseases) A major new clinical trial seeks to determine whether HIV-infected asymptomatic individuals have less risk of developing AIDS or other serious illness if they begin taking antiretrovirals sooner rather than later, based on...

TOPICS:
Advertisement

Psoriasis medication rises hope in the fight against multiple sclerosis

March 7, 2011 9:37 am | by EurekAlert | Comments

(Ruhr-University Bochum) Fumaric acid salts have been in use against severe psoriasis for a long time. About ten years ago, researchers in Bochum speculated that they may also have a favorable effect on multiple sclerosis as a result of their TH2 polarizing mechanisms. In parallel...

TOPICS:

Genzyme seeks shareholder OK on Sanofi deal

March 7, 2011 9:37 am | by Mass High Tech: The Journal of New England Technology | Comments

Genzyme Corp. said its board of directors unanimously recommends that shareholders accept the Sanofi-aventis revised tender offer to purchase all outstanding shares of Genzyme common stock for $74 and one contingent value right, per share.

Capacity expansion at OSRAM Opto Semiconductors

March 7, 2011 9:37 am | by I-Micronews | Comments

Conversion and expansion of chip manufacture at the Penang and Regensburg plants.

6? wafer capability for CPV solar applications

March 7, 2011 9:37 am | by I-Micronews | Comments

IQE are being recognised for developing epitaxial processes for producing high efficiency, triple junction concentrator photovoltaic (CPV) solar cells with comparable results on both 6 inch diameter germanium (Ge) and gallium arsenide (GaAs) substrates.

Repligen returns disappointing bipolar drug trial results

March 7, 2011 9:36 am | by Mass High Tech: The Journal of New England Technology | Comments

Repligen Corp. has announced its Phase 2b clinical trial results of a bipolar depression drug candidate, and the results for RG2417 did not show significant improvement in patients with bipolar depression.

Advertisement

IRIDEX to Present at the Roth OC Growth Stock Conference in Dana Point, CA

March 7, 2011 9:35 am | by Bio-Medicine.Org | Comments

MOUNTAIN VIEW, Calif., March 7, 2011 /- IRIDEX Corporation (Nasdaq: IRIX ) today announced that management is scheduled to make an investor presentation at the ROTH 23rd Annual OC Growth Stock Conference on Monday, March 14, at 2:30 pm Pacific Time.  The conference is being held...

TOPICS:

Reportlinker Adds Neuroprotection - Drugs, Markets and Companies

March 7, 2011 9:34 am | by Bio-Medicine.Org | Comments

NEW YORK, March 7, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Neuroprotection - Drugs, Markets and Companies http://www.reportlinker.com/p0203546/Neuroprotection---Drugs-Markets-and-Companies.html SummaryThis report describes the...

TOPICS:

Grifols Establishes Expert Advisory Council in Transfusion Medicine

March 7, 2011 9:33 am | by Bio-Medicine.Org | Comments

BARCELONA, Spain, March 7, 2011 /- Grifols, a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain today announced that it has established an Expert Advisory Council in Transfusion Medicine drawing on the expertise of internationally renowned physicians...

TOPICS:

Accurate measurement of radioactive thoron possible at last

March 7, 2011 8:37 am | by EurekAlert | Comments

(Physikalisch-Technische Bundesanstalt (PTB)) Annette Rottger and her scientific team managed to do something that was previously thought to be impossible: they developed a primary standard for the measurement of short-lived radioactive thoron.

TOPICS:

Parents important for keeping adolescents off alcohol

March 7, 2011 8:37 am | by EurekAlert | Comments

(Karolinska Institutet) Parents who are both present and engaged are the very best way of preventing teenagers from consuming large quantities of alcohol. Adolescents who smoke, stay out with their friends and have access to alcohol -- from their parents, for example -- when they...

TOPICS:

Boston Scientific Omega stent gets EU approval

March 7, 2011 8:36 am | by Mass High Tech: The Journal of New England Technology | Comments

Boston Scientific Corp. has won CE Mark approval for its Omega Platinum Chromium Bare-Metal Coronary Stent System, enabling the company to begin marketing the system in the European Union and other CE Mark nations.

RainDance forms deals with Ambry Genetics, Roche Group

March 7, 2011 7:35 am | by Mass High Tech: The Journal of New England Technology | Comments

Lexington-based biotech RainDance Technologies Inc. has landed a pair of deals for its microdroplet-based tools to be used in genetic screening systems, one with California-based Ambry Genetics and the second with a division of Roche Group.

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading